Inovio Pharmaceuticals, Inc. (INO)
NasdaqCM
Price as at 1 Oct 2026, 23:23 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Inovio Pharmaceuticals, Inc. trades at $1.21. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
5 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- D. E. Shaw, D. E. Shaw & Co., Inc.$1.49M · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$1.36M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$875.7K · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$397.5K · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$266.0K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in INO
Trades in INO disclosed by members of Congress and executive-branch officials, latest first:
- Christopher L. Jacobs · HouseSell · $1,001 - $15,000 · traded 8 Sept 2020 · disclosed 6 Nov 2020
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
Common questions
Which funds own INO?
5 of the institutions we track reported a position in INO in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its INO data?
Fundamentals for INO come from company filings and exchange data, as listed on NasdaqCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 23:23 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for INO, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.